MARKET

ONTX

ONTX

Onconova Therapeutics Inc
NASDAQ
1.160
+0.060
+5.45%
Opening 15:41 05/30 EDT
OPEN
1.090
PREV CLOSE
1.100
HIGH
1.170
LOW
1.090
VOLUME
81.99K
TURNOVER
50.51K
52 WEEK HIGH
1.520
52 WEEK LOW
0.6200
MARKET CAP
24.32M
P/E (TTM)
-1.1775
1D
5D
1M
3M
1Y
5Y
HC Wainwright & Co. Reiterates Onconova Therapeutics (ONTX) Buy Recommendation
NASDAQ · 4d ago
Onconova Therapeutics (ONTX) Gets a Buy from H.C. Wainwright
TipRanks · 5d ago
HC Wainwright & Co. Reiterates Buy on Onconova Therapeutics, Maintains $11 Price Target
Benzinga · 5d ago
Onconova Therapeutics Announces Dosing Of First Participant In Investigator-Sponsored Phase 2 Trial Of Rigosertib Plus Pembrolizumab In Metastatic Melanoma Patients Refractory To Immune Checkpoint Blockade
Benzinga · 5d ago
Onconova Therapeutics (ONTX) Gets a Buy from Noble Financial
TipRanks · 05/16 12:05
Analysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX), Cara Therapeutics (CARA) and Minerva Neurosciences (NERV)
TipRanks · 05/16 10:20
BRIEF-Onconova Therapeutics Reports First Quarter 2023 Financial Results And Provides Business Update
Reuters · 05/15 21:45
Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates
NASDAQ · 05/15 21:35
More
About ONTX
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on discovering and developing products for patients with cancer. It has molecularly targeted agents designed to disrupt specific cellular pathways for cancer cell proliferation. It has the two clinical-stage programs: narazaciclib (ON 123300), which is a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib administered alone or in combination for the treatment of solid tumors. Narazaciclib targets cyclin-dependent kinases (CDK's), AMPK related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R) at low nM concentrations as well as other tyrosine kinases. It is also engaged in supporting investigator-initiated studies (IIS) that explores the use of rigosertib for cancers driven by mutated K-Ras genes, including a Phase I/IIa study of rigosertib with a PD-1 inhibitor.

Webull offers kinds of Onconova Therapeutics Inc stock information, including NASDAQ:ONTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONTX stock methods without spending real money on the virtual paper trading platform.